Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11497743B2 · kind B2 · utility
3Cited by
14References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2020 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Dec 4, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.